| Aug 26 |
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
|
| Aug 22 |
Tevogen Bio gets $6M series C Preferred Stock Investment
|
| Aug 22 |
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
|
| Aug 14 |
Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
|
| Aug 9 |
Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
|
| Jul 11 |
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
|
| Jul 10 |
Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
|
| Jun 21 |
Tevogen Bio files to sell 42.5M shares, plans to offer shares and warrants for holders
|
| Jun 18 |
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
|
| Jun 12 |
Tevogen Bio Set to Join Russell 3000® Index
|
